Please use BHARAT IMMUNOLOGICALS BIOLOG fundamental data analysis to find out if markets are at this time mispricing the company. We found twenty-three available financial indicators for BHARAT IMMUNOLOGICALS which can be compared to its peers in the sector. To make sure the equity is not overpriced, please confirm all BHARAT IMMUNOLOGICALS BIOLOG fundamentals including its Operating Margin, Revenue, Debt to Equity, as well as the relationship between Price to Earning and Net Income . Use BHARAT IMMUNOLOGICALS to protect your portfolios against small markets fluctuations. The stock experiences very speculative upward sentiment. Check odds of BHARAT IMMUNOLOGICALS to be traded at 6.18 in 30 days.
Chance of Financial Distress
BHARAT IMMUNOLOGICALS BIOLOG has more than 51 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info
BHARAT IMMUNOLOGICALS competes with PANACEA BIOTEC, Tiaan Ayurvedic, AAREY DRUGS, and PARNAX LAB. Bharat Immunologicals Biologicals Corporation Limited, a biotechnology company, manufactures and markets a range of pharmaceuticals products in India. The company was founded in 1989 and is based in Bulandshahr, India. BHARAT IMMUNOLOGICALS operates under Biotechnology classification in India and is traded on Bombay Stock Exchange.
BHARAT IMMUNOLOGICALS Shares Outstanding vs Price to Sales
BHARAT IMMUNOLOGICALS BIOLOG is rated second in shares outstanding category among related companies. It is rated third in price to sales category among related companies . The ratio of Shares Outstanding to Price to Sales for BHARAT IMMUNOLOGICALS BIOLOG is about 143,933,333
BHARAT IMMUNOLOGICALS Market Fundamentals
BHARAT IMMUNOLOGICALS August 19, 2019 Opportunity Range